All Oncology News

Frontline iza-bren in combination with serplulimab was associated with a tolerable and manageable safety profile and elicited responses in ES-SCLC.

Osimertinib plus chemotherapy prolonged PFS vs osimertinib alone in patients with advanced NSCLC harboring concurrent EGFR and TP53 mutations.

R. Lor Randall, MD, FACS, highlights primary objectives of, and key takeaways from, the BOOM consensus meeting on PJI management in orthopedic oncology.

Megan Kruse, MD, discusses the use of imaging modalities in breast cancer management and emphasizes the role of FES-PET/CT in identifying ER presence.

The NCCN has added the IBCG risk stratification model for intermediate-risk NMIBC to its Clinical Practice Guidelines in Oncology for bladder cancer.

PANGEA-SMM outperforms existing predictive tools by more accurately determining when smoldering multiple myeloma is progressing and requires treatment.

The FDA approved relacorilant plus nab-paclitaxel for previously treated platinum-resistant epithelial ovarian/fallopian tube/primary peritoneal cancer.

Glofitamab combined with CAR T-cell therapy is associated with improved outcomes in relapsed/refractory B-cell lymphoma.

Read on to see what abstracts experts in the field of lung cancer are interested in learning more about at ELCC 2026 in Copenhagen, Denmark.

Obe-cel is associated with durable survival outcomes in relapsed/refractory B-ALL, regardless of BOR of CR or CRi.

Study led by Roswell Park’s Dr. Brian Betts and Dr. Shernan Holtan highlighted in Blood Advances.

Selinexor plus ruxolitinib met the SVR co–primary end point but missed the symptom score end point in the phase 3 SENTRY trial in myelofibrosis.

Neil Mendhiratta, MD, MS, and Toni K. Choueiri, MD, discuss the current and future treatment landscape of kidney cancer during Kidney Cancer Awareness Month.

Rapcabtagene autoleucel exhibited promising response and safety data in relapsed or refractory B-cell acute lymphoblastic leukemia.

Tebentafusp use was associated with frequent dermatologic AEs, with desquamation and hypopigmentation observed in non-White patients in a real-world analysis.

Updated data from TRANSCEND FL showed durable efficacy outcomes with liso-cel in relapsed/refractory follicular lymphoma.

Sensitivity analyses accounting for new primary melanoma did not diminish the RFS benefit favoring adjuvant pembrolizumab vs placebo in high-risk stage II melanoma.

PFS was improved when patients with advanced EGFR exon 20 insertion–positive NSCLC received sunvozertinib vs platinum chemotherapy in the first line.

Tafasitamab has been approved by ANVISA for the treatment of relapsed or refractory follicular lymphoma.

Marla D. Lipsyc-Sharf, MD, discusses the evolving role of MRD ctDNA testing in breast cancer management and aiding in early detection of disease recurrence.

Chemo therapy delivered in the home of patients has shown feasibility and safety according to researchers at Mayo Clinic

Limited knowledge of long-term irAEs points to the need for more concentrated research regarding optimal postimmunotherapy toxicity management.

The top 5 OncLive TV videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, lung cancer, breast cancer, and prostate cancer.

The FDA has cleared nivolumab/AVD for classical Hodgkin lymphoma, accepted a bezuclastinib NDA for review in nonadvanced systemic mastocytosis, and more.

Pathologists play a key role in lung cancer care, from biomarker testing to tissue triage.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Nadofaragene firadenovec has been added to the NCCN guidelines in BCG-unresponsive papillary NMIBC without CIS.

The FDA has approved nivolumab plus AVD for adult and pediatric patients with previously untreated stage III or IV classical Hodgkin lymphoma.

CNS-penetrant TKIs are reshaping brain metastases care in lung cancer, shifting sequencing decisions between systemic and local therapy.

Jorge Cortes, MD, discusses available TKIs and how to navigate optimal treatment selection for patients with chronic myeloid leukemia.